// App-Quantinova.ai

PO1625 : PHYOX3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients with Primary Hyperoxaluria Type 1, 2, or 3

Researchers

Presenter

  • Coenen Martin

Principal Investigators

  • Schalk Gesa

  • Cochat Pierre

  • Lipkin Graham

  • Lieske JohnC

  • Groothoff Jaap

  • Baum MichelleAmy

  • Hoppe Bernd

  • Rosskamp Ralf

Medical Centers

  • University Hospital Bonn, Bonn, Germany

  • Hôpital Femme Mere Enfant HCL Bron France

  • Queen Elizabeth Hospital, Birmingham, United Kingdom

  • Mayo Clinic Minnesota Rochester Minnesota United States

  • Amsterdam UMC (Academic Medical Center), Amsterdam, Netherlands

  • Boston Chidlren's Hospital Boston Massachusetts United States

  • Dicerna Pharmaceuticals Inc. Lexington Massachusetts United States

Locations

  • Germany

  • France

  • United Kingdom

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Genetic Disorder

Disease

  • Primary hyperoxaluria type 1

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved